BMS-986497 (ORM-6151)
Phase I Multicenter, Open-Label, First-in-Human Study of BMS-986497 (ORM-6151) as a Monotherapy, in Double Combination With Azacitidine and in Triple Combination With Azacitidine and Venetoclax in Subjects With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Near Add Your Location
Center of Excellence
John Theurer Cancer Center at Hackensack University Medical Center
Hackensack Meridian Health
Hackensack, NJ
- Accepting patients
- Accepting patients
Center of Excellence
Massachusetts General Hospital
Boston, MA
- Accepting patients
Center of Excellence
Herbert Irving Comprehensive Cancer Center (Columbia University)
Columbia University Medical Center
New York, NY
- Accepting patients
Center of Excellence
- Accepting patients
Center of Excellence
Robert H. Lurie Comprehensive Cancer Center
Northwestern University Feinberg School of Medicine
Chicago, IL
- Accepting patients
Real People. Real Support.
Need help connecting with this clinical trial? We're here to help!
Print a patient-friendly report to share with your patient.
We can help answer any questions and connect you (or your patient) with the study team.
Schedule a time that is convenient and we’ll call you to see how we can help you and your patient.